KRAS Mutation Testing in Advanced Colorectal Cancers

Main Article Content

Shanop Shuangshoti, MD

Abstract

KRAS is an oncogene located on the short arm of chromosome 12 (12p12.1). The gene is a member of the Ras family of small guanine nucleotide–binding proteins, first identified as a cellular homolog of a  transforming gene in the Kirsten rat sarcoma virus.1 Activating mutations in KRAS have been noted in a variety of human cancers,  including carcinomas of the pancreas, lung (non-small cell lung cancer), and colorectum (Table 1). KRAS mutations are frequently found in exon 1 (codons 12 and 13) and exon 2 (codon 61).2 Mutations in KRAS codons 12 and 13 have been associated with lack of response to EGFR-targeted therapies in patients with colorectal cancer (CRC)(Table 2).

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Shuangshoti S. KRAS Mutation Testing in Advanced Colorectal Cancers. BKK Med J [Internet]. 2011Feb.18 [cited 2020Dec.5];1(1):63. Available from: https://he02.tci-thaijo.org/index.php/bkkmedj/article/view/217665
Section
Reviews Article

References

1. Wang HL, et al. KRAS mutation testing in human cancers: the pathologist’s role in the era of personalized medicine. Adv Anat Pathol 2010;17:23-32
2. Whitehall V, et al. A Multicenter blinded study to evalu- ate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn 2009;11:543-552
3. Lièvre A, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26: 374-379
4. Amado RG. Wild-type KRAS is required for panitumu- mab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634
5. Allegra CJ, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carci- noma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-2096
6. Monzon FA, et al. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med 2009;133:1600-1606